Fellowship research focus | Outputs and outcomes |
---|---|
Development of a methodology (e.g., laboratory protocol or standard operating procedure) | A medicinal chemistry doctoral student from Kenya improved chemical inhibition phenotyping assays used to predict drug-drug interaction potential of new molecular entities [23]; the method was subsequently transferred to the H3D Drug Discovery and Development Centre at the University of Cape Town where he was completing his PhD studies. |
A pharmacologist from Tanzania developed a rapid and reliable reversed phase high performance liquid chromatography method for simultaneous determination of selected anti-retroviral agents and lumefantrine in human plasma [24]; the method was successfully transferred to her home laboratory, facilitated completion of her PhD, and is being used by other post-graduate students at that institution researching HIV-malaria co-infection. | |
A molecular biologist from Argentina developed a high-throughput screening assay for a drug target for Brucella abortus, the causative organism for brucellosis, a zoonotic infection that affects livestock and humans. Ten compounds with promising potency were identified after screening 44,000 compounds. This work facilitated completion of her doctoral thesis [25, 26] and formed the basis of a successful grant application at her research institute in Buenos Aires. | |
A pharmacologist from Nigeria evaluated the herb-drug interaction potential of natural products in common use in his country [27, 28]. This facilitated the completion of his doctoral studies and transfer of the in vitro metabolism study methods to his institution in South Africa, and helped to enable his subsequent post-doctoral and faculty appointment. | |
A cellular and molecular biologist from Brazil conducted laboratory studies to develop mechanistic understanding of cell surface immune responses of helper T cells. This facilitated continuation of his doctoral studies on Chagas disease [29]. The methodologies were used by his home laboratory to conduct in vitro assays to examine the role of the different T-cell subsets and cytokines in disease progression. | |
Training on planning or conduct of clinical trials | A medical doctor from South Africa obtained practical skills in operational planning and execution of first-in-human (FIH) studies [14] that were subsequently applied to a FIH study of a malaria drug candidate discovered at H3D in partnership with Medicines for Malaria Venture [30]. She continues with an active clinical pharmacology research agenda including studies to understand pharmacogenetics and clinical response [31]. |
A medical oncologist from Brazil worked with an early clinical development team to learn procedures relating to trial protocol amendments. This facilitated direct interaction with in-house experts for input into her doctoral studies [32,33,34,35]. Upon return to her clinic in Brazil, she continued as clinical investigator on multiple oncology translational medicine clinical studies. | |
A medical doctor from Ethiopia compared mechanistic explanations of drug induced liver injury across multiple publicly available clinical candidates [36]. He also acquired clinical trial skills and networks to establish a clinical pharmacology unit [14] after his return to Ethiopia, and has an active senior role in multiple aspects of clinical research. | |
Access to laboratory equipment, infrastructure and expertise | A geneticist from South Africa documented genetic diversity in Black South Africans from Soweto, learned bioinformatics techniques, and constructed a large database of African genetic diversity for further analyses and training purposes [37]. |
A geneticist from South Africa identified a novel mutation in the CHST6 gene as a cause of macular corneal dystrophy in a Black South African family, which was used for genetic counselling of the family [38]. | |
A drug formulation scientist from Kenya assessed alternate liposomal parenteral formulations to solubilize poorly soluble drug substances while working with the nano-technology unit. He applied these technologies to potential anti-malarial drug formulations [39, 40] as part of his doctoral studies. He currently collaborates with South African scientists and their team has been successful in grant applications relating to malaria research. | |
Analysis of samples or data from the fellow’s own institution | A medicinal chemist from Kenya evaluated the metabolism and pharmacokinetics for a series of new deoxyamodiaquine-based compounds. This work was directly applied to the drug discovery program at H3D [41]. |
A pharmacognocist/phytochemist from Ghana assessed natural products to demonstrate anti-plasmodial and medicinal potential [42, 43]. These initial studies played a key role in the expansion of the natural products research laboratory at his home institution. |